Tagged: MEQ

Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014

— Innovative cardiology solutions help deliver better care for more patients, respond to biggest challenges facing cardiologists

ANDOVER, Mass., Aug. 29, 2014 /PRNewswire/ – Royal Philips (NYSE: PHG AEX: PHIA) today announced its presence at the European Society of Cardiology (ESC) Congress 2014, where the company is highlighting the full range of its cardiology solutions serving clinicians and patients across the care continuum from prevention and diagnosis, to treatment, recovery and wellness. Visitors to the Philips booth (#F500) will experience Philips’ new Cardiology Solutions approach, enabling clinicians and health systems to deliver better cardiovascular care for more patients, at lower a cost, in the treatment of coronary artery disease, structural heart disease, and heart failure.

Photo – http://photos.prnewswire.com/prnh/20140828/141270
Photo – http://photos.prnewswire.com/prnh/20140828/141271
Photo – http://photos.prnewswire.com/prnh/20140828/141269
Photo – http://photos.prnewswire.com/prnh/20140828/141268
Photo – http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

Philips Cardiology Solutions meet the needs of clinicians who are at the center of the cardiovascular care. Philips’ breadth of diagnostic and treatment solutions offer real-time tools to connect patient information with clinician knowledge, resulting in more personalized care, while innovations for recovery and wellness provide a safer transition from hospital to home.

“Interventional cardiology is continuously innovating new procedures to improve the lives of patients around the world,” said Gene Saragnese, CEO of Imaging Systems for Philips Healthcare. “Our cardiology solutions approach unlocks the data and insights necessary to improve efficiency in interventional cardiology, and together with our global customers and partners, we’re creating care delivery to optimally support clinicians and patients.”

One of the leading global conferences on cardiovascular care, the ESC Congress 2014 will showcase the industry’s most promising research and leading innovations. Throughout the event, Philips and physician partners will be participating in several symposia and presentations on topics including big data in cardiology and anatomical intelligence.

On Saturday, August 30th, Philips’ newest ultrasound system will make its worldwide debut, with an unveiling at the Philips Booth (#F500) at 4 p.m. CET.  Beginning August 30th  and running through September 3rd at the ESC Congress 2014, Philips will also offer demonstrations of its advanced imaging and ultrasound solutions designed for every step of the patient journey, including:

Screening and Diagnosis

  • ST80i ECG Stress Testing System – Manages patient information from start to finish through bi-directional network connectivity and turns stress ECG data into actionable insights.
  • Philips IntelliSpace ECG – A multi-modality, multi-vendor, scalable ECG management system, providing access to patient data for review of time-sensitive ECGs on a smartphone, to help improve patient care through comprehensive and flexible workflow management.
  • Xcelera Image Management System – Integrated, multi-modality image management system for cardiovascular information offering access to multiple applications within a single flexible workspace for use in multiple locations and across multi-sites.
  • IntelliSpace Portal with TAVI package – Quickly assesses the aortic root anatomy for pre-TAVI planning and obtains crucial information about eligibility, proper device size, and a recommendation for C-arm angle for device deployment.
  • EPIQ Ultrasound – Philips’ most powerful architecture ever applied to ultrasound imaging.

Treatment

  • Allura Clarity with ClarityIQ – Industry-leading interventional X-ray system offering high image quality at a low [X-ray] dose.
  • EchoNavigator R2 with Image Fusion – Fuses live X-ray and live echo for intuitive, live image guidance during structural heart disease procedures.
  • Hybrid OR – Provides the ability to seamlessly perform a wide range of open and minimally invasive procedures in a single room.
  • Heart Navigator – Supports structural heart disease procedures by simplifying planning, device and projection angle selection and providing live image guidance to support device positioning.

Recovery and Care Management

  • Q-Station, with anatomical intelligence tools – Streamlines ultrasound data management and performs advanced visualization, analysis and quantification of Philips echo data.
  • Motiva mobile – A content rich and interactive telehealth platform that is part of the Chronic Ambulatory Care program (eCAC), specifically designed to help empower chronically ill patients to effectively manage their disease state.

For more information on Philips presence at the ESC Congress 2014, please visit http://www.philips.com/esc, follow the #ESCcongress conversation @PhilipsHealth and continue the conversation via the Philips LinkedIn Innovations in Cardiology Group

For more information, please contact:
Kathy O’Reilly
Philips Healthcare
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 113,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market

— Collaborations with academia and hospitals will be vital for development of multi-disciplinary technologies

KUALA LUMPUR, Malaysia, Aug. 27, 2014 /PRNewswire/ — Higher disposable incomes and the rapid penetration of health insurance are fuelling the demand for medical devices in Asia-Pacific. With the rise of medical tourism, the inflow of patients requiring medical and surgical intervention is further increasing. The market will continue its steady ascent as the region’s burgeoning population becomes increasingly vulnerable to age-related and non-communicable diseases, compelling significant investments in the domestic manufacturing of medical devices.

New analysis from Frost & Sullivan, 2014 Asia-Pacific Medical Devices Outlook, finds that the market earned revenues of US$53.13 billion in 2013 and estimates this to reach US$98.97 billion in 2018. The study, which analyses the opportunities, business models, medical device market revenues, and region-wise market, covers cardiac, orthopedic, wound care and wound closure, and minimally invasive surgery devices.

“The need for faster recovery, accuracy, and precision to ensure early discharge from hospitals will drive the development of new technology in medical device products,” said Frost & Sullivan Healthcare Consultant Poornima Srinivasan. “Manufacturers are also turning to frugal innovation, designing ‘as-is’ products to meet the needs of a domestic market burdened by rising healthcare costs.”

This is crucial as healthcare spending in most Asia-Pacific countries remains conservative, with tight budgets stalling consumer expenditure on expensive equipment. To counter this, manufacturers need to leverage proper distribution strategies and aggressively launch cost-effective yet high-quality, sustainable business products.

Contract manufacturing will become a common trend, since multinational products are exorbitantly priced and many governments have liberalized policies for domestic manufacturing. Partnering with ancillary services available in Asia-Pacific countries too could bring down the cost of products.

“As regional production gathers pace, and considering the multi-disciplinary nature of medical device technologies, industry integration with academia and hospitals is vital,” noted Srinivasan. “Such collaboration will aid technology transfer, improve competitiveness, and ultimately strengthen industry understanding of healthcare and services needs in the region.”

If you are interested in more information on this study, please send an e-mail to Donna Jeremiah, Corporate Communications, at djeremiah@frost.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.

2014 Asia-Pacific Medical Devices Outlook is part of the Advanced Medical Technologies (http://www.medtech.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Global Emerging Interventional Cardiac Devices Market, Endoscopy Devices Market in Australia, South Korea, and Southeast Asia, and Image-guided Surgery and Robot-assisted Surgery Market in Asia-Pacific. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on “the next big thing”
Register:         Gain access to visionary innovation

2014 Asia-Pacific Medical Devices Outlook
P7D5-54

Contact:
Donna Jeremiah
Corporate Communications – Asia Pacific
P: +61 (02) 8247 8927
F: +61 (02) 9252 8066
E: djeremiah@frost.com

Carrie Low
Corporate Communications – Asia Pacific
P: +603 6204 5910
F: +603 6201 7402
E: carrie.low@frost.com

Melissa Tan
Corporate Communications – Asia Pacific
P: +65 6890 0926
F: +65 6890 0999
E: melissa.tan@frost.com

http://www.frost.com

Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China

SHANGHAI, Aug. 27, 2014 /PRNewswire/ — Global design and architecture firm NBBJ announced today the expansion of its healthcare planning and design services into China. Principal Rudy Widjaja will lead planning and design teams from NBBJ’s Shanghai office, where he will draw on his experience with healthcare clients in mainland China, Taiwan, Korea and the United States, as well as the firm’s global network of healthcare experts.  

The launch of NBBJ’s China healthcare practice comes at a time when the scope of the firm’s healthcare practice in Asia is increasing, with work for Shanghai Children’s Medical Center in mainland China; the Koo Foundation Sun Yat-Sen Cancer Center in Taipei, Taiwan; and the Samsung Medical Center in Seoul, Korea, among other projects.

Joan Saba, AIA, FACHA, Partner at NBBJ and the leader of its global healthcare practice, said: “We’ve successfully extended our innovative healthcare facilities concepts across the U.S., Europe and the Middle East. While we have long been serving select healthcare clients in China, we are very excited to deepen our practice by building a strong China team for future clients.”

“By formalizing our healthcare practice, we are now able to bring NBBJ’s renowned healthcare design expertise to our Chinese clients more readily. We can adapt best and future practices to the specific technical and cultural needs in China as new private healthcare models emerge,” added Principal Rudy Widjaja.  

For seventy years, NBBJ’s vision and compassion have helped shape many of the world’s most progressive academic medical centers, teaching hospitals, specialty hospitals, community hospitals, ambulatory care centers, medical office buildings and specialty facilities. NBBJ has worked with 11 of the top 17 U.S. News & World Report Honor Roll Hospitals. Clients include American University of Beirut Medical Center, Brigham and Women’s Hospital (a teaching affiliate of Harvard Medical School), Cambridge University, the Children’s Hospital of Philadelphia, Cleveland Clinic, Kaiser Permanente, the Kuwait Ministry of Health, Mayo Clinic, Massachusetts General Hospital, NYU Langone Medical Center, the Royal Liverpool University Hospital, the University of Pennsylvania Health System and Virginia Mason.

The firm successfully blends healing environments with efficient, evidence-based design and research. This approach has earned NBBJ notable accolades, including being named “Firm of the Year” and “Healthcare Architect of the Year” (for Joan Saba) by Healthcare Design and “Most Admired Healthcare Firm” by Interior Design for seven consecutive years. NBBJ is ranked as the second-largest healthcare architect in the world, according to BD World Architecture, and by Engineering News-Record as the “#1 Green Architecture Firm.” The firm has been the recipient of more than 300 healthcare design awards.

In the late 1990s, NBBJ formed a team to meet clients’ demand for services in a rapidly growing Asia market, which led to the opening of the Shanghai office in 2005. In China, NBBJ is currently designing corporate offices for Alipay in Hangzhou, Suning in Nanjing, Tencent in Shenzhen and WeChat in Guangzhou. Commercial mixed-use developments include Yanlord Landmark in Chengdu and Eton Place in Xiamen. Recent sports and convention centers include the Hangzhou Olympic Sports Center in Hangzhou, the Asia World Expo in Hong Kong and the Qingdao Aoshan Bay International Exhibition Center. The firm’s master planning work spans the country, from the waterfront redevelopment of the Shanghai Bund to the 25,000-hectare city master plan for Karamay. NBBJ is the recipient of multiple MIPIM Asia, Cityscape and ASLA awards for its work in China.

To celebrate the expansion of the Chinese healthcare practice, NBBJ Partners Joan Saba and Timothy Johnson as well as Principal Rudy Widjaja are hosting a salon event, “Healthy China: What’s Next for Healthcare and Cities,” which will take place at The Langham, Xintiandi Shanghai, September 15, 2014, from 6:00 to 9:00 pm.

The invitation-only salon is a platform for discussion and knowledge sharing among leaders, thinkers and builders of health practice and health facilities. The format for the evening will be a panel discussion moderated by the Editor-in-Chief of Forbes (China) magazine, Jiangong Zhou. Panelists include John Cai, Director, Centre for Healthcare Management and Policy, and Adjunct Professor of Economics, China Europe International Business School (CEIBS); Hongyang Wang, Professor, School of Architecture and Urban Planning, Nanjing University; Joseph D. Tucker, Director, UNC Project-China; and Joan Saba, Healthcare Design Partner, NBBJ.

For more information:
US: Helen Dimoff, Director of Communications, NBBJ, hdimoff@nbbj.com
China: Stella Ye, stella.ye@motto-consulting.com.cn

For more information on the event:
http://www.nbbj.com/news/2014/8/11/healthy-china-whats-next-for-healthcare-and-cities/

To request an invitation to the event:
Cindy Wu, cwu@nbbj.com

About NBBJ
NBBJ creates innovative places and experiences for organizations worldwide, and designs environments, communities and buildings that enhance people’s lives. Founded in 1943, NBBJ is an industry leader in healthcare and corporate facilities and has a strong presence in the commercial, civic, science, education and sports markets. The firm has won numerous awards and has been recognized as one of the world’s “Top Ten Most Innovative Architecture Firms” by Fast Company magazine. NBBJ has more than 750 employees in ten offices worldwide, including Beijing, Boston, Columbus, London, Los Angeles, New York, Pune, San Francisco, Seattle and Shanghai. Clients include Alibaba, Amazon, the Bill & Melinda Gates Foundation, Boeing, Cambridge University, Cleveland Clinic, GlaxoSmithKline, Google, Massachusetts General Hospital, Microsoft, Reebok, Salk Institute, Samsung, Stanford University, Starbucks, Telenor, Tencent and the Wellcome Trust.

http://www.nbbj.com

Frost & Sullivan: Multi-Modality Breast Imaging Systems Spur Innovations in Europe

– Vendors focus on multi-modality equipment that improves the efficiency, specificity and sensitivity of breast cancer screening

LONDON, Aug. 26, 2014 /PRNewswire/ — National population-based screening programs for asymptomatic women aged 40 and above have been established in many European countries for early detection of breast cancer. With every passing year, this population cohort is expanding, spurring breast cancer screening rates and fuelling the need for breast imaging systems. With the number of women being diagnosed with breast cancer also bound to increase, the adoption of equipment for procedures such as biopsy and image guidance too will grow.

Logo – http://photos.prnewswire.com/prnh/20140826/139581

New analysis from Frost & Sullivan, Analysis of the European Breast Imaging Systems Market, finds that the market earned revenues of $988.3 million in 2013 and estimates this to reach $1,384.2 million in 2020. The study covers x-ray mammography, breast ultrasound, breast magnetic resonance imaging (MRI), molecular breast imaging (MBI), and breast computer-aided detection (CAD).

While mammography has been considered the ‘gold standard’ for breast screening, adjunct technologies such as breast ultrasound, breast MRI and MBI too are gaining traction as they improve the standards of diagnosis and treatment of breast cancers.

“The European market will continue to evolve as breast imaging systems vendors look for innovative technologies to battle the increasing rate of false positives and overcome limitations while scanning women with dense breast tissue,” said Frost & Sullivan Healthcare Research Analyst Raghuraman Madanagopal. “3-D tomosynthesis, automated breast ultrasound and MBI are the results of such technological innovations that ensure maximum efficiency and minimum error rates.”

However, sporadic reimbursement trends across countries may lead to equally sporadic uptake of these advanced modalities for breast imaging. While the more commonly performed mammography and the less expensive ultrasound procedures are reimbursed sufficiently, the trend changes for costly procedures such as MRI and MBI.

To overcome this restraint, many breast imaging facilities in Europe are employing multi-modality screening. This, in turn, is expected to drive the use of supplementary modalities such as breast ultrasound.

“Research studies in recent years have validated the benefits that multi-modality screening provides over regular mammography screening, since one modality can overcome the limitations of another,” noted Madanagopal. “In accordance with this validation that a multi-modality approach improves the efficiency, specificity and sensitivity of breast cancer screening procedures, a wide product portfolio will be a core competitive factor in the European breast imaging systems market.”

If you are interested in more information on this study, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

Analysis of the European Breast Imaging Systems Market is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: US Nuclear Medicine and PET Imaging Systems Market, and European Ultrasound Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com

http://www.frost.com

Logo – http://photos.prnasia.com/prnh/20140826/8521404802LOGO

Frost & Sullivan Applauds Volpara Solutions’ Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer

Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging

MOUNTAIN VIEW, Calif., Aug. 26, 2014 /PRNewswire/ — Based on its recent analysis of the breast imaging solutions market, Frost & Sullivan recognizes Volpara Solutions with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Volpara Solutions offers an innovative range of volumetric breast imaging solutions for the early detection of breast cancer. Over the past few years, the company has steadily introduced several new solutions and has expanded its global reach to cover the United States, Europe, Asia and Australia.

Volpara’s suite of quantitative solutions includes VolparaDose, VolparaDensity, VolparaAnalytics and VolparaResearch. The Density and Dose solutions are patient-specific, while the Analytics and Research solutions are clinic-wide monitoring tools.

VolparaDensity automatically generates an objective measurement of volumetric breast density and a FDA-cleared BI-RADS breast density category, while VolparaDose helps keep track of patient-specific dose exposure. VolparaAnalytics assists in quality assurance by monitoring critical elements of the breast imaging process and generating key metrics to help understand the performance of technologists, readers, and mammography and tomosynthesis machines. VolparaResearch is aimed at research facilities that are looking to analyze large datasets of breast measurement information captured across time.

“Frost & Sullivan lauds Volpara Solutions for continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging, and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer. Furthermore, all of the applications are built to serve across both full-field digital mammography and digital tomosynthesis systems, and with multi-vendor compatibility and reproducible data,” said Frost & Sullivan Research Director, Advanced Medical Technologies Group, Siddharth Saha. “This is of high relevance in the industry, as tomosynthesis is quickly gaining currency, with 30 percent of the members of the Society of Breast Imaging in the U.S. already using it.”

VolparaDose, along with VolparaAnalytics, gives radiologists patient-specific quantitative data to help minimize dose in mammography and tomosynthesis while maintaining image quality. While several market participants offer breast density measurement tools, Frost & Sullivan confirms that Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging. It is necessary to measure volumetric breast density to control the dose, and Volpara Solutions has emerged as a pioneer in leveraging the Mega Trend of Dose Reduction by acknowledging patient-specific dose tracking and reporting as a white-space opportunity.

Furthermore, by enabling radiologists to track density and dose scores across time, Volpara Solutions helps support the movement toward the personalization of breast screening. Women with lower density have a lower risk of breast cancer, and researchers are looking at incorporating breast density into risk models that may support personalized screening protocols, which can include the best adjuvant imaging options for that woman (including breast tomosynthesis, automated whole breast ultrasound, molecular breast imaging, and breast MRI) as well as the frequency of screening.

“We are very proud to be recognized for the innovative solutions we have brought to the breast imaging market and for our vision and commitment to address unmet needs in the detection, prevention and treatment of breast cancer,” noted Ralph Highnam, Ph.D., Volpara Solutions’ CEO and chief scientist. “By allowing researchers across the globe to compare data to detect geographical, racial and age-related trends, we hope to take breast cancer research to the next level, which could lead to the development of predictive analytical models that will revolutionize early detection of breast cancer and save lives.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About Volpara Solutions

Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Matakina’s founders and Board of Directors include John Hood, Ph.D., former Vice Chancellor of the University of Oxford, UK; Ralph Highnam, Ph.D., former CEO of Mirada Solutions, one of the University of Oxford’s most successful spin-outs of recent times, and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford, where he was Professor of Information Technology for 25 years.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:        Gain access to visionary innovation

Contact:

Frost & Sullivan            

Volpara Solutions

Mireya Espinoza             

Chris Joseph

P: 210. 247.3870            

P: 510.339.2293

F: 210.348.1003             

E: chris.joseph@volparasolutions.com

E: mireya.espinoza@frost.com

 

 

Golden Meditech Announces the Disposal of Convertible Note Issued by CCBC for over US$88 million

HONG KONG, Aug. 25, 2014 /PRNewswire/ — Golden Meditech Holdings Limited (the “Company” or “Golden Meditech”, 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has entered into an agreement to sell its 7% senior convertible note due 2017 in an aggregate principal amount of US$50 million issued on 3 October 2012 by China Cord Blood Corporation (“CCBC”), a non-wholly-owned subsidiary of the Company (“Convertible Note”) to Magnum Opus International Holdings Limited (“Magnum”) and Cordlife Group Limited (“CGL”) for approximately US$88,090,000 (equivalent to approximately HK$682,697,500) in cash (the “Disposal”). Upon completion of the Disposal, each of Magnum and CGL will hold 50% of the Convertible Note.

Magnum is a private vehicle controlled by Mr. Kam Yuen, Chairman and Chief Executive Officer of the Company and Chairman of CCBC, and involves the CCBC management team. CGL is a cord blood banking services operator listed on the main board of the Singapore Exchange Securities Trading Limited, which currently owns approximately 10% of the issued shares of CCBC.

Following completion of the Disposal, Golden Meditech’s shareholding in CCBC will remain unchanged at approximately 42.0% and will only be diluted to approximately 33.9% if both Magnum and CGL exercise their rights to convert their Convertible Note into CCBC shares and, accordingly, their respective shareholdings in CCBC would increase by approximately 9.7%.

With mainland China’s healthcare sector continues to be driven by the government’s healthcare reform, Golden Meditech believes the Disposal would strengthen its financial position and liquidity, enhancing its ability to fund its potential acquisitions or expansion of its existing healthcare related businesses in mainland China.

The transaction is subject to Golden Meditech and CGL obtaining all relevant approvals and consents, including but not limited to the approval of Golden Meditech’s independent shareholders. An Extraordinary General Meeting (“EGM”) will be convened to consider and approve the transaction and a circular containing details of the Disposal and a notice of EGM are expected be dispatched to the shareholders no later than 16 September 2014.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.

PW Medtech 2014 Interim Adjusted Net Profit Surged 53.6% to RMB102.3 Million

HONG KONG, Aug. 22, 2014 /PRNewswire/ — PW Medtech Group Limited (“PW Medtech” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 1358), a leading medical device company in China, today announced its interim results for the six months ended 30 June 2014 (the “period”). Adjusted net profit was approximately RMB102.3 million, representing an increase by 53.6% over the corresponding period in 2013. During the period, gross profit was approximately RMB190.7 million, representing an increase of 29.4% when compared to corresponding period last year. Profit attributable to owners of the Company amounted to approximately RMB84.1million, representing an increase of 68.2% from approximately RMB50.0 million for the corresponding period in 2013.

Financial Highlights

For the year ended June 30 (RMB Million)

2014

(Unaudited)

2013

(Unaudited)

Change (%)

Revenue

268.2

218.8

+22.6%

Gross profit

190.7

147.4

+29.4%

Gross profit margin

(71.1%)

(67.4%)

(+3.7pts)

Profit attributable
to owners of the Company

84.1

50.0

+68.2%

Adjusted net profit *

102.3

66.6

+53.6%

Note *: To supplement its consolidated financial statements which are presented in accordance with HKFRS, the Group also uses adjusted net profit as an additional financial measure to evaluate the financial performance by eliminating the impact of items that the Group does not consider indicative of the performance of its business. The Group’s adjusted net profit was derived from its net profit for the year excluding share-base compensation expenses, listing-related expenses as well as the expenses incurred in the acquisition of Tianxinfu.

During the period, revenue amounted to RMB268.2 million, representing an increase of 22.6% over the corresponding period last year. The advanced infusion sets business and orthopedic implant maintained growth, providing a stable development for the Group. The two core business of the Group recorded continuous growth. Revenue of advanced infusion sets business and orthopedic implant and were RMB183.9 million and RMB84.3 million respectively, which contributed 68.6% and 31.4% to the Group’s revenue.

Mr. Jiang Liwei, Chief Executive Officer of PW Medtech said, “The continuous process of urbanization, the increasing government investments into public healthcare sector and aging population contributed to growing demand for quality medical services; thus brought significant growth opportunities for China’s medical device industry. As the leading company in orthopedic implant and advanced infusion sets industry, PW Medtech has further expanded its product portfolio and manufacturing capacity, enhanced the innovation and R&D capabilities, extended domestic distribution network and diversified the product line by strategic acquisitions. The Group successfully entered into the biological materials segment and neurosurgery segment, which has massive growth potential and prospects, and therefore created new profit growth drivers.”

Acquisition of Tianxinfu and Enter the Biological Materials Segment and Neurosurgery Segment

In August 2014, the Group’s wholly-owned subsidiaries, Health Forward Holdings Limited and Beijing Fert Technology Co., Ltd., completed the acquisition of the entire equity interest in Beijing Tianxinfu Medical Appliance Co., Ltd. (“Tianxinfu”) with a total consideration of approximately RMB802.6 million. Tianxinfu has become an indirect wholly-owned subsidiary of the Group and contributed its revenue to it. Tianxinfu is a high-tech enterprise integrating R&D production and sales services. Its main products include regenerative medical biological materials and orthopedic implant products. The medical biological material segment is a segment with massive growth potential and prospects in China’s medical device industry. Upon completion of the acquisition, the Group will enter into the biological materials segment and created new profit growth drivers. The Group opt to expand biological material products applications to more area with R&D investment and technological improvement. After the acquisition of Tianxinfu, the Group will obtain huge neurosurgical medical devices segment distribution network in China. Meanwhile, the Group will also further expand the market share through synergy between the Company and Tianxinfu’s R&D, production and distribution capabilities;

Expansion of Product Portfolio

In order to fully seize market opportunities in the advanced infusion set and orthopedic implant markets, the Group continued to broaden the product portfolio by strengthening its R&D efforts and entering into strategic acquisitions.

With regard to the infusion sets business, the Group has been developing a series of advanced infusion set products with new functions and features. In view of delivering safer and improved infusion treatments, the Group plans to enhance the precision filter infusion sets by including more precise filter pore sizes, new features such as precise flow control, automatic air venting, etc. Further, in an effort expand the Group’s non-PVC-infusion set portfolio, improve product features and broaden its applications fields, the Group is currently developing new non-PVC materials, in order to replace the existing PVC-based infusion set.

The orthopedic implant business had seen much progress with the Group’s continued research on perfecting the three main product categories: trauma products, spine products and joint products. For the trauma implants, the Group is seeking to further improve properties of the bridge-link combined fixation system which was commercially launched in July 2012; the spine implants sees the on-going development of the PEEK (polyethereth erketone) fusion cage and vertebro plasty tools. The Group will continue to devise new ideas and develop advanced materials to satisfy varied patient demands for the hip and knee implants.

As for regenerative medical biological materials business, Tianxinfu has been working with large scale Class III hospital to upgrade the current products to develop a series of regenerative medical biological materials products with new applications, functions and features in order to diversify product portfolio.

Emphasis on Innovation and Research and Development

As a leader in development of innovative products, the Group currently possesses an experienced R&D team comprising of approximately 100 members. As at June 30, 2014, the Group has obtained 50 patents, including 25 for infusion set products and 25 for orthopedic implant products, and has applied for 34 patents. The Group will continue to invest in product innovation and R&D in future, and cooperate closely with surgeons, hospitals, university research centers and other research institutions to integrate results from R&D and develop products which meet market demands.

Expansion of Distribution Network

The Group currently has three experienced and dedicated sales and marketing teams to support and consolidate nationwide distribution network and strengthen product promotion. Approximately 50% of the sales and marketing staff who have medical experience; with key salespersons in each business segment have an average of 10 years’ experience in their respective areas. Their experience and expertise helps them to communicate with doctors and nurses in a succinct and effective manner.

In response to the ever-increasing market demand, the Group will make further efforts to develop the sales and marketing teams in order for them to support the Group’s extensive distribution network and, promote the Group’s products and brand name to surgeons, nurses and hospitals. For the Orthopedic Implant Business, the Group will continue to focus on expanding its business at Class 2 hospitals in the second and third tier cities, and concentrate on developing sales and marketing capabilities for the newly acquired joint implant business. In relation to the advanced infusion set business, the Group will focus initially on the Class 3 hospitals in larger-than-average cities in the more developed regions of China, and then penetrate into smaller hospitals and cities.

Increase Production Capacity

In view of the growing potential of the orthopedic implants market in China, the increasing popularity of the advanced infusion sets is now replacing conventional infusion sets. In the next 3-5 years, in addition to expanding the capacity in the existing plants in Beijing, the Group is also planning to make an addition of two manufacturing plants in Linyi (Shandong province) and Pinggu (Beijing) to expand its production capacity for advanced infusion sets. Meanwhile, the Group sets to increase the production capacity of trauma and spine implants of the facility in Tianjin.

Mr. Jiang Liwei, Chief Executive Officer of PW Medtech concluded, “Looking forward, the Group will be seeking to identify fast-growing, high-margin and high-potential opportunities in the medical device industry by utilizing its capabilities on strategic acquisitions; giving support to the rapid business growth and consolidating market leadership in the medical device industry. While maintaining rapid organic growth of the two core business including orthopedic implant and advanced infusion sets segments, the Group will leverage on its outstanding acquisition and integration capability to support sustainable and rapid growth of the Group’s business. It is believed that through continuous effort in enhancing the overall operational efficiency and profitability, the Group will be able to bring satisfactory return to shareholders.”

To see the full version of this release, including financial tables, click here: http://photos.prnasia.com/prnk/20140822/8521404726-a

About PW Medtech Group Limited

Listed on the main board of Hong Kong Exchange on 8 November 2013, PW Medtech Group Limited is the leading medical device company in China, focusing on R&D, production and distribution of orthopedic implants and advanced infusion sets products. In August 2014, the Group successfully entered into the biological materials segment through the completion of its acquisition of Beijing Tianxinfu Medical Appliance Co., Ltd. The Group is one of the only two major domestic companies with a full product portfolio of orthopedic implants, as well as among the top advanced infusion sets enterprises in the PRC. The Group manages an extensive nationwide distribution network located across 30 provinces, municipalities and autonomous regions in China.

Issued by Porda Havas International Finance Communications Group for and on behalf of PW Medtech  Group Limited.

Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses

GREENWICH, Connecticut, Aug. 22, 2014 /PRNewswire/ — Aptuit LLC announces that Aptuit SSCI, located in West Lafayette, Indiana, has enhanced its capabilities in the areas of structure determination and characterization of small and large molecules, including biologic drugs, metabolites, and polymers, through the addition of the Bruker maXisPlus Q-TOF mass spectrometer.

In making the announcement, Dr. Jonathan Goldman, CEO, Aptuit, said, “The expanded large molecule capability enhances our early development support for the fastest growing sector of the pharmaceutical industry and provides our scientists with the ability to identify active and/or high percentage metabolites in drugs as outlined in the United States Food and Drug Administration Guidance on Metabolites in Safety Testing (MIST).”

Dr. Patrick Tishmack, Director of Analytical Development at Aptuit SSCI, explained that ultra high mass resolution is particularly important in conducting impurity assays of drug substances and drug products, with a limit of detection in the pg/mL to fg/mL range. He clarified the significance of the high sensitivity by saying, “Q-TOF mass spectrometry is a fast and accurate analytical method for characterizing low levels of analytes yet its range from 20 Da to 40,000 Da also enables the analyses of small molecules, polymers, carbohydrates, oligonucleotides, and proteins such as antibodies.”

According to Dr. Tishmack, this addition brings significant value to Aptuit’s clients. “When high resolution mass spectrometry capability is coupled with Aptuit SSCI’s industry-leading expertise in solid state chemistry, the resulting data and corresponding expert scientific interpretation will be at a standard that is unmatched in the contract preclinical research industry.”

The Q-TOF MS, which will be installed and operational by October 2014, will allow unambiguous assignment of molecular formulae for small molecules. In addition to faster sample analysis, generally easier method development is achieved through its implementation. The equipment’s higher throughput translates into a more rapid turnaround for a large number of samples.

For more information, please send an email to info@ssci-inc.com or contact Aptuit SSCI at + 1 800 375 2179.

Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Pharmaceutical Sciences and Aptuit INDiGO® (a fixed-cost program that accelerates drug development). Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 700 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com.

American Green Technology(R) Installs HRMS Technology in Plastic Surgery Clinic in Hong Kong

SOUTH BEND, Ind., Aug. 20, 2014 /PRNewswire/ — American Green Technology® (AGT) has installed their innovative Health Risk Management System (HRMS) in a plastic surgery center in Hong Kong. The CorVic Skin and Facial Rejuvenation Clinic specializes in professional analysis and high-quality medical, skin and facial treatments and skincare services. A clinic like CorVic is just one of numerous applications that are ideal for the HRMS. Other traditional healthcare facilities include; hospitals, outpatient surgery centers, nursing homes, long-term care facilities, dental offices and cancer infusion centers, to name a few.

“The installation of the HRMS technology provides a clear advantage in protecting our patients and staff against deadly HAIs,” said CorVic Partner, Ms. Cory Cho, “Patient care is our utmost priority. It is important our customers realize that we take their safety, health and well-being very seriously. That is why we decided to utilize the HRMS technology for added security against dangerous pathogens. It offers a great peace of mind.”

According to the World Health Organization, hundreds of millions of patients are affected by HAIs worldwide each year, leading to significant mortality and financial losses for health care facilities. Out of every 100 hospitalized patients, 7 will acquire at least one HAI. The patented, unobtrusive lighting system offers a barrier against 99.7% of hazardous HAI-causing bacteria and viruses like MERS, MRSA, Staph and even Tuberculosis.

To learn more about the HRMS log onto arcaluxhrms.com.

About American Green Technology:

American Green Technology® (AGT) is a company dedicated to developing innovative products to positively impact the health, economy, and environment of global communities. AGT’s Health Risk Management System (HRMS) is a patented UVC lighting product clinically proven to eliminate 99.7% of airborne pathogens that cause Healthcare-associated Infections (HAIs) in hospitals and cancer centers.

About CorVic:

Clinic CorVic consists of a team of plastic surgeon and experienced therapists providing professional analysis and high-quality medical skin and facial treatments and skincare services. We monitor each step of our treatments carefully to provide our clients professional services, and comprehensive and effective treatments.​ We use the world’s top notch skin treatment equipment with the most advanced technologies, all FDA and CE certified. Client-centricity is the core principle of CorVic, and we ensure that all our treatments and products are safe and reliable. To learn more, log onto www.corvicclinic.com.

Contact:

Meredith Jimenez, Corporate Communications Director
Email mjimenez@agtus.org Office +1-269-769-2510

Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures

Atonarp announces $8 million in funding led by Walden Riverwood Ventures to accelerate the development of its Smart Spectrometer platform, which will enable next-generation oil & gas and healthcare measurement instruments

TOKYO, August 20, 2014 /PRNewswire/ — Tokyo-based Atonarp Inc. announced today $8 million in a Series A funding round led by Walden Riverwood Ventures with participation from other co-investors. The funding accelerates the development of Atonarp’s Smart Spectrometer technology platform, which will enable a broad range of applications. The company has targeted the oil & gas and healthcare industries for its initial products.

“We are excited to partner with Atonarp in pursuing the commercialization of its Smart Spectrometer platform. Atonarp has a unique combination of engineering, semiconductor and data analysis talent and fundamental technologies. These are being used by Atonarp to create disruptive, next generation measurement instruments,” said Nicholas Brathwaite, co-founder of Walden Riverwood Ventures and Chairman of Atonarp, Inc.

Atonarp is pioneering the field of chemical composition analysis by combining state-of-the-art electronics and data processing algorithms. Atonarp’s Smart Spectrometer will enable manufacturers of gas-composition analysis instruments, such as field-based gas chromatography equipment, to achieve breakthrough improvements in cost, size, accuracy and maintenance-free operation. The Smart Spectrometer platform is also enabling novel use cases and applications for manufacturers of medical equipment and patient devices, including non-invasive personal healthcare monitoring.

Atonarp is currently sampling its Smart Spectrometer platform to leading manufacturers of oil & gas and healthcare instruments, and will enter volume production early next year.

About Walden Riverwood Ventures

Walden Riverwood Ventures is a venture capital firm focused on investing in core technology companies globally. It was formed as a collaboration between Walden International, a leading international venture capital firm, and Riverwood Capital, a global, technology-focused private equity firm. The firm’s founding partners provide its portfolio companies with unique access to deep industry knowledge, relationships and management experience. The two firms have an established history of investing together in several successful companies such as GoPro, Ambarella, Inc., and Aptina Imaging, Inc. Walden Riverwood Ventures leads early stage investments in companies developing fundamental technologies that have the potential to benefit multiple industry verticals. For further information, please visit www.waldenintl.com and www.riverwoodcapital.com.

For more information, please contact:
Cesar Lee
cesar@rwcm.com
70 Willow Road, Suite 100
Menlo Park, CA 94025
(650) 618-7313